Choose a language and wait for the translated text.
The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.
European Commission approves Novartis’ Itvisma to treat SMA | PharmaVoice
